1. Introduction
===============

Neurofibromatosis is inherited dominant disease that is prone to a number of tumors. It can be divided into 2 types: neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2). NF1 is caused by heterozygous mutation of tumor suppressor gene *NF1*, and NF2 is caused by mutations in the *NF2* gene on chromosome 22. Checkpoint kinase 2 (CHEK2) is a serine/threonine kinase that is activated upon DNA damage, and is involved in DNA repair, cell cycle arrest, and apoptosis.^\[[@R1]\]^ When activated, it phosphorylates a number of substrates, including tumor suppressor gene *P53*, and *BRCA1*, and *CHEK2* gene thus acts as a tumor suppressor gene.^\[[@R2]\]^ Mutation of *CHEK2* was reported to be associated with elevated risk for breast cancer and other familiar cancers.^\[[@R1],[@R3]\]^

Currently, there is no direct evidence supporting the role of *CHEK2* in NF pathogenesis. Nevertheless, mutation of this gene is involved in impaired DNA damage repair, which can cause chromosomal instability in NF2.^\[[@R4]\]^ In this article, we report for the first time an identical germline *CHEK2* mutation, p.R180C, in a Tibetan boy with NF1 and in a Chinese girl with NF2, and discuss the significance of *CHEK2* and other genetic mutations in tumorigenesis of this disease.

2. Patient and methods
======================

2.1. Patient history
--------------------

### 2.1.1. Patient 1

A 7-year-old Tibetan boy complained of painful subcutaneous mass in the right frontotemporoparietal region for 4 years. He underwent tumor resection on the same site 4 years before admission, and pathology showed plexiform neurofibroma. After that, he experienced slow regrowth of the tumor. On physical examination, the tumors were nodular, plexiform, and located under scalp on the right side. They were painful with moderate movability. He had multiple café-au-lait spots all over his body, and mass on his head was painful (Fig. [1](#F1){ref-type="fig"}). The patient underwent tumor resection under general anesthesia. His postoperative course was uneventful. Pathology confirmed previous diagnosis of plexiform neurofibroma and NF1. Because the boy is the only one with neurofibroma in his family, his parents expressed concern for heredity of the disease, and we discussed gene mutation test with patient\'s parents and obtained informed consent. Peripheral blood was drawn from the patient, his sister, and both his parents for subsequent tests.

![Clinical photograph of patient with neurofibromatosis type 1 (NF1). A, Multiple café-au-lait spots on the abdomen. B, Gross specimen of the plexus neurofibroma after resection.](medi-97-e10894-g001){#F1}

### 2.1.2. Patient 2

A 12-year-old girl complained of decreased eyesight for 7 years. She had total loss of vision in her right eye about 4 months before admission, and before that, she did not tell her parents about her illness. On physical examination, there was bulging mass in her left frontal bone. Her right eye was completely blind, and visual acuity in her left eye was almost normal. Her bilateral hearing decreased, which was worse for her left ear. Her computed tomography (CT) scan showed choroidal plexus calcification in bilateral ventricles. Reconstructed skull CT scan showed expansion and erosion of her left frontal bone. On enhanced magnetic resonance imaging scan, there was thickening and enhancement in her left frontal bone and adjacent meninges. Also noticed was enhanced mass in her right optic nerve and bilateral vestibular masses. In addition, there were multiple enhanced masses in suprasellar region and lower posterior fossa (Fig. [2](#F2){ref-type="fig"}). An initial diagnosis of NF2 was made. Because she was not deaf in either of her ears and the chance of recovering her right eyesight was almost zero, we did not attempt to remove the vestibular schwannoma or right optic nerve tumor; instead, her main concern was the mass in her left frontal bone. She underwent skull and meningeal lesion removal with cranioplasty under general anesthesia. She recovered well and pathology confirmed World Health Organization grade I meningioma with invasion to skull and NF2. Her parents were concerned with heredity of the disease, and we performed gene mutation test for the girl and her parents using peripheral blood under informed consent. Both studies were reviewed and approved by Ethnic Committee of West China Hospital, and both patients' guardians provided informed consent for publication of these cases.

![Pre- and postoperative images for patient with neurofibromatosis type 2 (NF2). A, Computed tomography (CT) scan showing thickening of left frontal bone and calcification of bilateral choroidal plexus. B, 3D-reconstructed CT scan showing bulging and erosion of left frontal bone. C, Sagittal enhanced magnetic resonance imaging (MRI) showing thickening of frontal bone and enhancement of underlying meninges. D, Sagittal enhanced MRI showing suprasellar mass. E, Coronal image showing enhanced mass on the right optic nerve, possibly optic glioma. F, Axial image showing bilateral vestibular schwannoma. G, Axial image on lower pons and medulla section showing multiple neuromas of cranial nerve in the posterior fossa. H, Postoperative CT scan showing removal of affected bone and cranioplasty.](medi-97-e10894-g002){#F2}

2.2. gDNA extraction
--------------------

AllPrep DNA/RNA mini Kit (Qiagen 80204) was used for gDNA extraction from blood lymphocytes according to the instructions. The gDNA was qualified with a 2200 Bioanalyzer (Agilent Technologies) in fragment size, quality and total concentration.

2.3. Library construction
-------------------------

The library of gDNA was constructed according to the manufacturer\'s protocols by a KAPA Hyper Prep kit (Kapa Biosystems). The quantities of the library were all measured with Qbit 3 (Thermo Fisher).

2.4. Panel design and targeted sequencing
-----------------------------------------

A panel of 139 were used in our research (gene are listed in supplementary files), gDNA libraries were enriched for regions of this custom designed captured probe manufactured by Agilent. A total of 750 ng prepared libraries were hybridized with 2 different hybridization reagents and blocking agents in SureSelectXT Target Enrichment System (Agilent Technologies). The enriched libraries were amplified with P5/P7primer. After qualified by the 2200 Bioanalyzer and quantified with Qbit3 and a qPCR NGS library quantification kit (Agilent Technologies), then the libraries were sequenced on a Hiseq X10 platform (Illumina, San Diego, CA).

2.5. Data analysis
------------------

Sequencing reads were mapped to a human reference genome (hg19) using the Burrows--Wheeler Aligner.^\[[@R5]\]^ Duplicate removal, local realignment, and base quality recalibration were performed using PICARD (<http://broadinstitute.github.io/picard/>) and the Genome Analysis Toolkit (GATK).^\[[@R6]\]^ Somatic single nucleotide variations and small indels were called using GATK.^\[[@R6]\]^ Effects of variants were annotated using Oncotator^\[[@R7]\]^ and Variant Effect Predictor,^\[[@R8]\]^ as well as an in-house database (GnentronDB). A mutation was filtered if the depth was smaller than 5, the mutational frequency was less than 20%, or was recurrently found in healthy individuals. Each candidate mutation was reviewed visually by integrative genomics viewer.^\[[@R9]\]^

3. Results
==========

In patient 1, he inherited CHEK2 mutation from his mother, and polymerase epsilon (POLE) mutation from his father (Fig. [3](#F3){ref-type="fig"}). In patient 2, she inherited CHEK2 mutation from her mother, but not MutL homolog 1 (MLH1), colon cancer, nonpolyposis type 2 (*E coli*), and she inherited both mutY DNA glycosylase, earlier mutY Homolog (MUTYH), and ataxia telangiectasia mutated and rad-related kinase (ATR) mutations from her father. NF2 mutation was also detected (Fig. [4](#F4){ref-type="fig"}).

![Pattern of germline mutation of patient with neurofibromatosis type 1 (NF1). CHEK2 = checkpoint kinase 2, POLE = polymerase epsilon.](medi-97-e10894-g003){#F3}

![Pattern of germline mutation of patient 2. ATR = ataxia telangiectasia mutated and rad-related kinase, CHEK2 = checkpoint kinase 2, MUTYH = mutY DNA glycosylase, earlier mutY homolog.](medi-97-e10894-g004){#F4}

4. Discussion
=============

This is the first article to report that identical germline mutation of *CHEK2* gene, p.R180C, exists in both NF1 and NF2 patients, and the first article to show coexistence of germline mutation of CHEK2 and POLE in a Tibetan child. These genes are involved in DNA synthesis, repair of mutation, and proofreading, all of which are critical steps in normal cell division and errors could cause tumorigenesis. *CHEK2* as a tumor suppressor gene is activated in response to DNA damage, and can prevent cell from entering mitosis or arrest cell cycle. It was reported that CHEK2 mutation was associated with elevated risk of breast cancer, colorectal cancer, Li-Fraumei syndrome and other early-onset familiar cancers.^\[[@R1]--[@R3],[@R10],[@R11]\]^ Our findings demonstrate that *CHEK2* mutation could also be associated with both NF1 and NF2.

CHEK2∗1100delC allele is the most widely studied mutation point and is associated with Li-Fraumei syndrome. The risk of breast cancer in its carriers varies in different ethnic groups, with the highest in Russian and Brazilian populations, but in Southeast Asia, CHEK2∗1100delC allele is rarely detected.^\[[@R1]\]^ The rate of p.R180C mutation was reported to be 0.6% in Ashkenazi Jewish breast cancer patients and 0.38% in Chinese patients.^\[[@R1],[@R12]\]^ Although this mutation is not located in a functional domain, it may affect protein folding and is deemed intolerant, and further study in yeast *Rad53* gene, an equivalent to human *CHEK2*, confirms that it is pathogenic.^\[[@R13]\]^ In Chinese population, the *CHEK2* mutation p.H371Y has only been recently reported to be associated with Li-Fraumei--like syndrome.^\[[@R11]\]^ Otherwise, there is no report concerning the p.R180C mutation in either NF1 or NF2 patients.

Human POLE is the catalytic subunit of POLE complex. It is responsible for synthesis of leading strand during DNA replication, and is capable of proofreading, which is essential for replication fidelity.^\[[@R14]\]^ Mutation of this gene is involved in impaired DNA damage repair,^\[[@R4]\]^ which is a key mechanism in DNA mismatch repair deficiency (MMRD) syndrome, characterized by early onset of hematological and brain tumors, as well as cutaneous features similar to café-au-lait spots in NF1 patients.^\[[@R15],[@R16]\]^ Recently, the phenotype overlap between NF1 and MMRD has been reported, raising the hypothesis that NF1 and MMRD may share some common pathogenic mechanism.^\[[@R17]--[@R19]\]^

*MUTYH* gene is located in the short arm of chromosome 1 (1p34.1) and encodes human DNA glycosylase that is associated with DNA repair, specifically base excision repair pathway.^\[[@R20]\]^ It removes adenine from oxidized form of guanine, and mutation of MUTYH is related to a condition vulnerable to colorectal cancer called MUTYH-associated polyposis (MAP). Most MAP patients harbor somatic G:C to T:A transversion mutation in adenomatous polyposis coli and Kras genes.^\[[@R20]\]^ ATR, together with ataxia telangiectasia mutated kinase (ATM), are critical mediators in response to DNA damage. ATR mainly activates Chek1 in response to ultraviolet damage, whereas ATM activates p53 and Chek2 in response to ionizing radiation damage. Recently, ATM has been shown to be required for ATR recruitment and later activation of Chek1, which subsequently activates a number of substrates that function in cell-cycle arrest, replication forks stabilization and DNA repair.^\[[@R21]\]^

More than 2600 inherited mutations leading to NF1 have been reported. Although germline mutation rate of NF1 is approximately 10 times higher than other inherited disease genes, more than half of NF1 is caused by de novo mutations.^\[[@R22]\]^ We did not perform somatic gene mutation test in the neurofibroma tissue from our first case, because it is usually very difficult to identify the causative NF1 mutation due to its large size (350 kbp), structural complexity and lack of mutation hotspot and clusters. No germline mutation of NF1 was detected in the Tibetan boy. It is noteworthy that only the boy who harbored both *CHEK2* and *POLE* mutation was inflicted by NF1, and not those who harbored either one mutation, such as his sister or parents. Therefore, it is possible that *CHEK2* and *POLE* germline mutation would work synergistically to evoke tumorigenesis of NF1 in the child. In addition, some MMRD patients present symptoms and signs indistinguishable from NF1 patients before the early onset of malignant tumors, and although the role of *POLE* in MMRD has been confirmed,^\[[@R16]\]^ our case suggests that in addition to *POLE* mutation, *CHEK2* mutation might also contribute to development of MMRD. However, the role of *CHEK2* germline mutation in MMRD needs further study.

In the second case, the girl inherited mutation of MUTYH and ATR from her father and *CHEK2* from her mother. It was reported that ATR-Chek1 pathway suppressed tumorigenesis, whereas ATM-Chek2 pathway might promote it.^\[[@R23]\]^ Germline mutations of both pathways coexisted in the second patient, but we do not know how these mutations affect function of the respective pathways and their interplay. Mutation of *MUTYH*, *ATR*, and *CHEK2* might have caused failure to correct de novo NF2 gene mutation during early embryonic stage before she was born, as germline mutation of NF2 was detected only in the girl, not her parents. This case suggests that de novo germline mutation of NF2 can occur when DNA repair mechanism is incompetent, and causes symptomatic NF2 phenotype.

It is interesting that germline mutation of *CHEK2* with the exact identical location (p.R180C) exists in both NF1 and NF2 patients in the present study, irrespective of ethnic differences. This suggests p.R180C mutation may not be rare for Asian population. Furthermore, since p.R180C is pathogenic, and inactivation of ATM-Chek2 and ATR-Chek1 pathway has been reported to sensitize human tumors to radio-/chemo-therapy based on cisplatin, temozolomide, topoisomerase inhibitor, and poly(ADP-ribose) polymerase inhibitor,^\[[@R23]\]^ our findings implicate possible role of these agents in systemic or adjuvant treatment of NF1 and NF2 patients.
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